TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27409462

Group type: EXPERIMENTAL
Intervention: OCT images during normoxia
Number of subjects: 20

Group type: COMPARATOR
Intervention: RVA images during normoxia
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: OCT images during 100% oxygen breathing
Number of subjects: 20

Group type: COMPARATOR
Intervention: RVA images during 100% oxygen breathing
Number of subjects: 20
Study: 27409470

Group type: EXPERIMENTAL
Intervention: Small incision lenticule extraction (SMILE) for treatment of myopia
Number of subjects: 23
Study: 27410906

Group type: EXPERIMENTAL
Intervention: 17β-estradiol treatment for 1.7 years (median duration) in 60 girls with CTS
Number of subjects: 304
Study: 27410923

Group type: EXPERIMENTAL
Intervention: Ipilimumab at a dose of 10 mg per kilogram every 3 weeks for a total of 4 doses, with additional doses every 12 weeks for up to 60 weeks in patients who had a clinical benefit.
Number of subjects: 28

Group type: COMPARATOR
Intervention: Ipilimumab at a dose of 3 mg per kilogram every 3 weeks for a total of 4 doses.
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Ipilimumab (both doses)
Number of subjects: 28
Study: 27411053

Group type: EXPERIMENTAL
Intervention: Pre-specified oral cancer associated genes (IL8, IL1, SAT, OAZ1, DUSP1, S100P)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Reference genes (MT-ATP6, RPL30, RPL37A, RPLP0, RPS17)
Number of subjects: 168
Study: 27411316

Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty (TKA)
Number of subjects: 0
Study: 27411369

Group type: EXPERIMENTAL
Intervention: Colonoscopy screening in cancer survivors treated with ART
Number of subjects: 54
Study: 27411451

Group type: EXPERIMENTAL
Intervention: High elastance group (H group, n = 14)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low elastance group (L group, n = 10)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pawstress index
Number of subjects: 24
Study: 27411450

Group type: EXPERIMENTAL
Intervention: Lung-protective ventilation (LPV)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Partially mandatory ventilation
Number of subjects: 104
Study: 27411452

Group type: EXPERIMENTAL
Intervention: Esmolol therapy
Number of subjects: 63
Study: 27411453

Group type: EXPERIMENTAL
Intervention: Early goal-directed therapy (EGDT)
Number of subjects: 19
Study: 27411683

Group type: EXPERIMENTAL
Intervention: IV nab-paclitaxel 260 mg/m² on day 1 plus IV cisplatin 75 mg/m² on day 1
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: IV nab-paclitaxel 140 mg/m² on days 1 and 8 plus IV cisplatin 75 mg/m² on day 1
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: IV nab-paclitaxel 100 mg/m² on days 1, 8, and 15 plus IV cisplatin 75 mg/m² on day 1
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Overall treatment (nab-paclitaxel plus cisplatin)
Number of subjects: 69
Study: 27411694

Group type: EXPERIMENTAL
Intervention: Daclizumab
Number of subjects: 36
Study: 27411699

Group type: EXPERIMENTAL
Intervention: DCCT intensive therapy (HbA1c ∼7%)
Number of subjects: 1441

Group type: COMPARATOR
Intervention: DCCT conventional therapy (HbA1c ∼9%)
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: Combined DCCT/EDIC cohort
Number of subjects: 1441

Group type: COMPARATOR
Intervention: DCCT conventional therapy with increasing mean HbA1c
Number of subjects: 1441
Study: 27412114

Group type: EXPERIMENTAL
Intervention: Newly diagnosed HIV infections (n=354, 32.42%)
Number of subjects: 1095

Group type: EXPERIMENTAL
Intervention: Current CD4+ T cell count
Number of subjects: 1095

Group type: EXPERIMENTAL
Intervention: Non-availability of HIV type (n=787, 72.07%)
Number of subjects: 1095

Group type: EXPERIMENTAL
Intervention: Chronic cough (n=32, 2.93%)
Number of subjects: 1095

Group type: EXPERIMENTAL
Intervention: Intake of co-trimoxazole (n=271, 24.82%)
Number of subjects: 1095

Group type: EXPERIMENTAL
Intervention: Vitamin supplementation (n=220, 20.15%)
Number of subjects: 1095

Group type: EXPERIMENTAL
Intervention: Use of mosquito bed nets (n=613, 56.14%)
Number of subjects: 1095
Study: 27412386

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg orally twice daily during chemoradiation, up to 1 week before surgery, and for 6 months following surgery; Irinotecan 65 mg/m2 and Cisplatin 30 mg/m2 weekly during chemoradiation with 5040 cGy radiation therapy
Number of subjects: 40
Study: 27412526

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium topical gel (1%), applied up to 4 times daily
Number of subjects: 35
Study: 27412562

Group type: EXPERIMENTAL
Intervention: Bevacizumab on Day 1, etoposide on Days 2-4, and cisplatin on Day 2 in a 21-day cycle for a maximum of 6 cycles
Number of subjects: 8
Study: 27412659

Group type: EXPERIMENTAL
Intervention: CE-SSFP
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: T2-STIR
Number of subjects: 215

Group type: COMPARATOR
Intervention: Myocardial perfusion single-photon emission computed tomography (reference standard)
Number of subjects: 215
Study: 27412867

Group type: EXPERIMENTAL
Intervention: Routine FFR assessment
Number of subjects: 918

Group type: EXPERIMENTAL
Intervention: Deferred lesions with FFR≤0.80
Number of subjects: 918
Study: 27412868

Group type: EXPERIMENTAL
Intervention: Everolimus-Eluting Stents (EES) for Bare-Metal Stent ISR
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Everolimus-Eluting Stents (EES) for Drug-Eluting Stent ISR
Number of subjects: 249
Study: 27412883

Group type: EXPERIMENTAL
Intervention: Intralesional injection of 20 million allogeneic adipose-derived stem cells in the vaginal walls and fistula tract, followed by a second dose of 40 million if necessary.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cytokine profiles and immunotoxicity assays monitoring.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Follow-up for serious adverse events or rejection issues.
Number of subjects: 10
Study: 27412889

Group type: EXPERIMENTAL
Intervention: CAR-BCMA T cells (4th dose level: 9 × 10(6) CAR(+) T cells/kg body weight)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CAR-BCMA T cells (lowest 2 dose levels)
Number of subjects: 12
Study: 27412903

Group type: EXPERIMENTAL
Intervention: ST-elevation in -aVR for STE-TTC
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: ST-elevation in -aVR with ST-elevation in inferior leads for STE-TTC
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: ST-elevation in -aVR with ST-elevation in anteroseptal leads for STE-TTC
Number of subjects: 400

Group type: COMPARATOR
Intervention: ST-elevation in aVR for STEMI
Number of subjects: 400

Group type: COMPARATOR
Intervention: ST-depression in V2-V3-V4 for STEMI
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: T-inversion in leads I-aVL-V5-V6 for non ST-elevation-TTC
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: ST-elevation in -aVR with T-inversion in any lead for non ST-elevation-TTC
Number of subjects: 400

Group type: COMPARATOR
Intervention: ST-depression in V2-V3 for non-ST elevation MI
Number of subjects: 400
Study: 27413040

Group type: EXPERIMENTAL
Intervention: Statin treatment (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor) for 12 months
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Statin treatment (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Obesity (BMI >30)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: C-reactive protein elevation
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 106
Study: 27413127

Group type: EXPERIMENTAL
Intervention: Diet behavior modification treatment (D group)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (C group)
Number of subjects: 110
Study: 27413577

Group type: EXPERIMENTAL
Intervention: Medication use at discharge
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Medication use at month 6
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Polypharmacy (number of categories of treatments received)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Presence of disturbances (depression, anxiety, sleep disturbances)
Number of subjects: 153
Study: 27414521

Group type: EXPERIMENTAL
Intervention: Oral Shilajit supplementation (250 mg b.i.d. for 8 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral Shilajit supplementation (250 mg b.i.d. for 8 weeks) with additional 4 weeks of supplementation with exercise
Number of subjects: 0
Study: 27414736

Group type: EXPERIMENTAL
Intervention: SVD
Number of subjects: 707

Group type: EXPERIMENTAL
Intervention: VSD
Number of subjects: 707

Group type: EXPERIMENTAL
Intervention: SVD with endothelial dysfunction
Number of subjects: 707

Group type: EXPERIMENTAL
Intervention: SVD or VSD with persisting or worsening angina
Number of subjects: 707
Study: 27415006

Group type: COMPARATOR
Intervention: No organ damage
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: CI-AKI
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: HLI
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: Combined CI-AKI and HLI
Number of subjects: 668
Study: 27415585

Group type: EXPERIMENTAL
Intervention: Educational intervention targeting primary care physicians' and community pharmacists' attitudes and knowledge
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 27415618

Group type: EXPERIMENTAL
Intervention: Supervised physical exercise program (PEP) including cycloergometry/kinesiotherapy plus nutritional therapy
Number of subjects: 29

Group type: COMPARATOR
Intervention: Nutritional therapy (control)
Number of subjects: 29
Study: 27416639

Group type: EXPERIMENTAL
Intervention: FocalyxDx (imaging)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: FocalyxBx (biopsy)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: FocalyxTx (treatment)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Focalyx app (follow-up)
Number of subjects: 300
Study: 27417011

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin assay
Number of subjects: 0
Study: 27418050

Group type: EXPERIMENTAL
Intervention: CYD-TDV dengue vaccine
Number of subjects: 3736

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3736
Study: 27418324

Group type: EXPERIMENTAL
Intervention: ILR monitoring after AF ablation
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Continuous monitoring
Number of subjects: 57
Study: 27418609

Group type: EXPERIMENTAL
Intervention: Combo stent
Number of subjects: 61
Study: 27418632

Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus ribavirin for 12 weeks
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus ribavirin for 16 weeks
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus ribavirin (12 or 16 weeks)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus ribavirin
Number of subjects: 321
Study: 27418646

Group type: EXPERIMENTAL
Intervention: Mogamulizumab, an anti-CCR4 monoclonal antibody
Number of subjects: 0
Study: 27418929

Group type: EXPERIMENTAL
Intervention: Levothyroxine suppression therapy (fixed dose)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (matched for age, sex, and BMI)
Number of subjects: 14
Study: 27419080

Group type: EXPERIMENTAL
Intervention: 50,000 IU vitamin D
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 27420134

Group type: EXPERIMENTAL
Intervention: Young Mania Rating Scale (YMRS)
Number of subjects: 3716

Group type: EXPERIMENTAL
Intervention: Montgomery-Asberg Depression Rating Scale (MADRS)
Number of subjects: 3716

Group type: EXPERIMENTAL
Intervention: Both scales (YMRS and MADRS)
Number of subjects: 3716
Study: 27420361

Group type: EXPERIMENTAL
Intervention: Presence of Tropheryma whipplei in different body sites
Number of subjects: 0
Study: 27421052

Group type: EXPERIMENTAL
Intervention: HIV status disclosure among couples
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Supportive spouse dynamics in discordant relationships
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Engagement of partners in testing
Number of subjects: 194
Study: 27421053

Group type: EXPERIMENTAL
Intervention: Mobile community health campaigns (CHCs)
Number of subjects: 334479

Group type: EXPERIMENTAL
Intervention: Mobile testing
Number of subjects: 334479

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 334479

Group type: EXPERIMENTAL
Intervention: Traditional masculine gender norms
Number of subjects: 334479
Study: 27421056

Group type: EXPERIMENTAL
Intervention: Universal ART intervention
Number of subjects: 3126
Study: 27421618

Group type: EXPERIMENTAL
Intervention: MCI subjects with above normal BMI (>25)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Greater physical activity in MCI subjects
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Healthier diet
Number of subjects: 44

Group type: COMPARATOR
Intervention: Physical activity in subjects with subjective memory impairment
Number of subjects: 44
Study: 27421763

Group type: EXPERIMENTAL
Intervention: Dynamic infrared thermography (DIRT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: CT angiography (CTA)
Number of subjects: 25
Study: 27422011

Group type: EXPERIMENTAL
Intervention: CONNECT intervention to improve staff communication
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: CONNECT intervention
Number of subjects: 83
Study: 27422150

Group type: EXPERIMENTAL
Intervention: Treatment after 8 weeks of acute period treatment in MDD patients
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Diagnostic test using questionnaire, neuropsychological assessment, and biomarkers in MDD patients
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Longitudinal study over 96 weeks including 8-week acute treatment and 88-week stable treatment in MDD patients
Number of subjects: 1200
Study: 27422279

Group type: EXPERIMENTAL
Intervention: 9vHPV vaccine
Number of subjects: 15000

Group type: COMPARATOR
Intervention: qHPV vaccine
Number of subjects: 15000
Study: 27422301

Group type: EXPERIMENTAL
Intervention: Olaparib 200 mg bid
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Olaparib 300 mg bid
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Olaparib 300 mg bid (expansion cohort)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Olaparib (all doses)
Number of subjects: 28
Study: 27422342

Group type: EXPERIMENTAL
Intervention: Postinfant series IgG concentration (age 7 months)
Number of subjects: 1754

Group type: EXPERIMENTAL
Intervention: IgG concentrations >0.61-5.58μg/mL
Number of subjects: 1754

Group type: EXPERIMENTAL
Intervention: IgG concentrations >2.48-17.69μg/mL
Number of subjects: 1754

Group type: EXPERIMENTAL
Intervention: High IgG concentrations
Number of subjects: 1754

Group type: EXPERIMENTAL
Intervention: Ethnicity
Number of subjects: 1754
Study: 27422389

Group type: EXPERIMENTAL
Intervention: Value Pricing (VP) with adherence-contingent rebates (50% or 25% rebate based on adherence of at least 90% or 75%)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 100
Study: 27423106

Group type: EXPERIMENTAL
Intervention: Lacosamide (target dose: 400mg/day by the end of titration) as adjunctive treatment to levetiracetam (LEV, stable dosage of >1000mg/day)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Lacosamide (target dose: 400mg/day) as adjunctive treatment to levetiracetam (LEV, stable dosage of >1000mg/day)
Number of subjects: 11
Study: 27423779

Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel 120 mg
Number of subjects: 33
Study: 27423899

Group type: EXPERIMENTAL
Intervention: Interferon β-1a biosimilar (various doses) via subcutaneous or intravenous injection in Trial A
Number of subjects: 24

Group type: COMPARATOR
Intervention: Biosimilar with albumin, biosimilar without albumin, and a comparator (three different formulations) via intravenous injection followed by multiple subcutaneous injections in Trial B
Number of subjects: 24
Study: 27427925

Group type: EXPERIMENTAL
Intervention: HIV/STD risk-reduction intervention
Number of subjects: 521
Study: 27428331

Group type: EXPERIMENTAL
Intervention: Simeprevir plus Peginterferon/Ribavirin (PR) for 12 weeks
Number of subjects: 163

Group type: COMPARATOR
Intervention: Simeprevir plus Peginterferon/Ribavirin (PR) for >12 weeks
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Baseline factors associated with SVR12
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Adverse events (AEs)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes
Number of subjects: 163
Study: 27428731

Group type: EXPERIMENTAL
Intervention: Sodium selenite (1000 µg loading dose followed by 1000 µg daily infusion until discharge, max 21 days)
Number of subjects: 1089

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1089

Group type: EXPERIMENTAL
Intervention: Procalcitonin guidance
Number of subjects: 1089

Group type: COMPARATOR
Intervention: No procalcitonin guidance
Number of subjects: 1089
Study: 27429035

Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y Gastric Bypass (LRYGB)
Number of subjects: 86
Study: 27430242

Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg/day) for 12 weeks
Number of subjects: 15
Study: 27430417

Group type: EXPERIMENTAL
Intervention: 12-week program consisting of a reduced calorie diet, increased physical activity, and behavioral modification
Number of subjects: 72
Study: 27430529

Group type: EXPERIMENTAL
Intervention: STEMO care (pre-hospital thrombolysis with alteplase)
Number of subjects: 658

Group type: COMPARATOR
Intervention: Conventional care (in-hospital thrombolysis)
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: STEMO care
Number of subjects: 658
Study: 27430708

Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 69
Study: 27430981

Group type: EXPERIMENTAL
Intervention: Thickened casein-based extensively hydrolyzed formula (eHCF, Allernova AR®)
Number of subjects: 30
Study: 27431598

Group type: EXPERIMENTAL
Intervention: Postoperative cardiac troponin-I (cTnI) measured at 24 hours after surgery
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Children undergoing surgery with cardiopulmonary bypass (CPB)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Postoperative cTnI concentrations
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: cTnI at 24 hours
Number of subjects: 169
Study: 27431901

Group type: EXPERIMENTAL
Intervention: Combination of 3 measures of immune cell function (neutrophil CD88, monocyte HLA-DR, % regulatory T cells)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood samples from critically ill patients undergoing whole blood staining for immune cell surface markers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secondary outcomes include death from severe infection (sepsis) and change in organ failure
Number of subjects: 0
Study: 27432417

Group type: EXPERIMENTAL
Intervention: Patient navigation intervention
Number of subjects: 4675

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 4675
Study: 27432875

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Number of subjects: 102
Study: 27432917

Group type: EXPERIMENTAL
Intervention: Ceritinib 750 mg/d
Number of subjects: 140
Study: 27433419

Group type: EXPERIMENTAL
Intervention: Minimally invasive lumbar interbody fusion (MILIF)
Number of subjects: 252
Study: 27433488

Group type: EXPERIMENTAL
Intervention: Metformin Extended Release (MXR) 2,000 mg daily
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: All groups (including MXR and placebo)
Number of subjects: 69
Study: 27433840

Group type: EXPERIMENTAL
Intervention: S100B protein
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Neuron-specific enolase (NSE)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Cognitive function assessment at 21 days and 6 months post-surgery
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: S100B protein vs NSE
Number of subjects: 88
Study: 27434039

Group type: EXPERIMENTAL
Intervention: ACUITY X4 leads (Spiral Long, Spiral Short, or Straight)
Number of subjects: 764
Study: 27435102

Group type: EXPERIMENTAL
Intervention: Cognitive delay (MDI <77)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive delay with normal motor development
Number of subjects: 0

Group type: COMPARATOR
Intervention: Psychomotor developmental index (PDI)
Number of subjects: 0
Study: 27435145

Group type: EXPERIMENTAL
Intervention: Real-time sensor glucose (SG) for treatment decisions
Number of subjects: 10

Group type: COMPARATOR
Intervention: Yellow Springs Instrument's (YSI) glucose analyzer
Number of subjects: 10
Study: 27435396

Group type: EXPERIMENTAL
Intervention: Osimertinib (AZD9291)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rociletinib (CO-1686)
Number of subjects: 0
Study: 27435453

Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: BsmI 'B' allele and TaqI 't' allele presence
Number of subjects: 73

Group type: COMPARATOR
Intervention: Age-matched controls
Number of subjects: 73
Study: 27435882

Group type: EXPERIMENTAL
Intervention: Tobramycin inhalation powder (TIP) for 1 year
Number of subjects: 157
Study: 27436099

Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg
Number of subjects: 16
Study: 27436274

Group type: EXPERIMENTAL
Intervention: Intensive diabetes therapy
Number of subjects: 1441

Group type: COMPARATOR
Intervention: Conventional diabetes therapy
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: Higher HbA1c levels
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: Lipid measurements
Number of subjects: 1441
Study: 27436285

Group type: EXPERIMENTAL
Intervention: Early stress-dose steroids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 27436749

Group type: COMPARATOR
Intervention: MJ-related cues
Number of subjects: 33
Study: 27436871

Group type: EXPERIMENTAL
Intervention: HeartMate 3 Left Ventricular Assist System (LVAS)
Number of subjects: 50
Study: 27436878

Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography-guided beating-heart mitral valve repair with expanded polytetrafluoroethylene cordal insertion (Harpoon TSD-5)
Number of subjects: 11
Study: 27436882

Group type: EXPERIMENTAL
Intervention: AngelMed Guardian System
Number of subjects: 0
Study: 27437054

Group type: EXPERIMENTAL
Intervention: GeneInsight Clinic (GIC) implementation
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GeneInsight Clinic (GIC)
Number of subjects: 8
Study: 27438106

Group type: EXPERIMENTAL
Intervention: Women with AF
Number of subjects: 10135
Study: 27438353

Group type: EXPERIMENTAL
Intervention: FeNO levels
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: FeNO levels of 31 ppb
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: FeNO levels of 0-20 ppb
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: FeNO levels of 21-40 ppb
Number of subjects: 70